On Tuesday, shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) are sinking, down over about 8.5% in mid-morning trading after the company announced a series of changes to its management team.
Alexion’s Chief Commercial Officer Carsten Thiel will resign effective June 1, and Brian Goff has been hired to succeed him. Goff has had many years of experience in the biopharmaceutical industry, working at firms like Neurovance, Baxalta, Novartis (NYSE:NVS) , and Johnson & Johnson (NYSE:JNJ) . He will lead all global operations, and be responsible for all country operations in each of Alexion’s affiliates in North America, Latin America, EMEA, Japan, and Asia Pacific.
Ludwig Hantson, Alexion’s Chief Executive Officer, stated, “We are delighted to welcome Brian to Alexion as our new Chief Commercial Officer and look forward to his leadership in developing and executing our strategies for long-term growth as we focus on creating value for all stakeholders.”
Current Chief Financial Officer Dave Anderson will resign from his position at the end of August; Martin Mackay, Executive Vice President, Head of Research & Development, will retire at the end of the year; and Executive Vice President, Chief Human Resources Officer, Clare Carmichael will be exiting Alexion, effective June 1, to pursue new opportunities. Searches and recruiting are currently underway to fill all three of these positions.
Alexion develops pharmaceutical products for the treatment of heart disease, inflammation, diseases of the immune system and cancer in humans. ALXN is a #3 (Hold) on the Zacks Rank, with a VGM score of ‘B.’
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Could you imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>
Novartis AG (NVS): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Original post
Zacks Investment Research